Immunological Effects of IAster yomena/I Callus-Derived Extracellular Vesicles as Potential Therapeutic Agents against Allergic Asthma

Plant-derived extracellular vesicles, (EVs), have recently gained attention as potential therapeutic candidates. However, the varying properties of plants that are dependent on their growth conditions, and the unsustainable production of plant-derived EVs hinder drug development. Herein, we analyzed...

Full description

Saved in:
Bibliographic Details
Published inCells (Basel, Switzerland) Vol. 11; no. 18
Main Authors Kim, Woo Sik, Ha, Ji-Hye, Jeong, Seong-Hun, Lee, Jae-In, Lee, Ba-Wool, Jeong, Yu Jeong, Kim, Cha Young, Park, Ji-Young, Ryu, Young Bae, Kwon, Hyung-Jun, Lee, In-Chul
Format Journal Article
LanguageEnglish
Published MDPI AG 01.09.2022
Subjects
Antiasthmatic agents
Asters
Asthma
Care and treatment
Chemical properties
Health aspects
Pharmacology, Experimental
Plant metabolites
Plant organelles
South Korea
Online AccessGet full text

Cover

More Information
Summary:Plant-derived extracellular vesicles, (EVs), have recently gained attention as potential therapeutic candidates. However, the varying properties of plants that are dependent on their growth conditions, and the unsustainable production of plant-derived EVs hinder drug development. Herein, we analyzed the secondary metabolites of Aster yomena callus-derived EVs (AYC-EVs) obtained via plant tissue cultures and performed an immune functional assay to assess the potential therapeutic effects of AYC-EVs against inflammatory diseases. AYC-EVs, approximately 225 nm in size, were isolated using tangential flow filtration (TFF) and cushioned ultracentrifugation. Metabolomic analysis, using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS), revealed that AYC-EVs contained 17 major metabolites. AYC-EVs inhibited the phenotypic and functional maturation of LPS-treated dendritic cells (DCs). Furthermore, LPS-treated DCs exposed to AYC-EVs showed decreased immunostimulatory capacity during induction of CD4[sup.+] and CD8[sup.+] T-cell proliferation and activation. AYC-EVs inhibited T-cell reactions associated with the etiology of asthma in asthmatic mouse models and improved various symptoms of asthma. This regulatory effect of AYC-EVs resembled that of dexamethasone, which is currently used to treat inflammatory diseases. These results provide a foundation for the development of plant-derived therapeutic agents for the treatment of various inflammatory diseases, as well as providing an insight into the possible mechanisms of action of AYC-EVs.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells11182805